Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

Go back to Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
(NASDAQ: SVRA) Delayed: 4.77 +0.01 (0.21%)
Previous Close $4.76    52 Week High $ 
Open $4.79    52 Week Low $ 
Day High $4.95    P/E N/A 
Day Low $4.76    EPS $ 
Volume 1,256,860